Marta Weinstock-Rosin
Directeur/Membre du Conseil chez Avraham Pharmaceuticals Ltd.
Postes actifs de Marta Weinstock-Rosin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Directeur/Membre du Conseil | - | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Historique de carrière de Marta Weinstock-Rosin
Anciens postes connus de Marta Weinstock-Rosin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| The Israel Society for Neuroscience | President | - | 01/01/2005 |
Spero Biopharma Ltd.
 Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Fondateur | - | - |
Statistiques
Internationale
| Israël | 5 |
Opérationnelle
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| President | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |
- Bourse
- Insiders
- Marta Weinstock-Rosin
- Expérience
